Stuart Holden - 26 Aug 2025 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Director
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Issuer symbol
URGN
Transactions as of
26 Aug 2025
Net transactions value
$0
Form type
4
Filing time
27 Aug 2025, 16:38:46 UTC
Previous filing
08 Aug 2024
Next filing
01 Dec 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Holden Stuart Director 400 ALEXANDER PARK DRIVE, PRINCETON /s/ Jason D. Smith, Attorney-in-Fact 27 Aug 2025 0001763999

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Stock Option (right ot buy) Award $0 +10,000 $0.000000 10,000 26 Aug 2025 Ordinary Shares 10,000 $19.50 Direct F1
transaction URGN Restricted Stock Unit Award $0 +8,000 $0.000000 8,000 26 Aug 2025 Ordinary Shares 8,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
F3 The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.